Virios Therapeutics, Inc. – NASDAQ:VIRI
Virios Therapeutics stock price monthly change
Virios Therapeutics stock price quarterly change
Virios Therapeutics stock price yearly change
Virios Therapeutics key metrics
Market Cap | 206.50K |
Enterprise value | N/A |
P/E | -0.45 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.80 |
PEG ratio | N/A |
EPS | -0.26 |
Revenue | N/A |
EBITDA | -5.20M |
Income | -5.07M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVirios Therapeutics stock price history
Virios Therapeutics stock forecast
Virios Therapeutics financial statements
| Jun 2023 | 0 | -1.44M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.23M | |
| Dec 2023 | 0 | -1.10M | |
| Mar 2024 | 0 | -1.29M |
| Dec 2023 | 0 | -1.10M | |
|---|---|---|---|
| Mar 2024 | 0 | -1.29M | |
| Oct 2025 | 0 | -962.89K | |
| Dec 2025 | 0 | -1.15M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -0.1 | -0.06 |
|---|---|---|
| 2024-02-29 | -0.09 | -0.06 |
| 2024-05-09 | -0.08 | -0.07 |
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 0% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 5212119 | 520.03K | 9.98% |
|---|---|---|---|
| Sep 2023 | 5248905 | 487.14K | 9.28% |
| Dec 2023 | 4165441 | 358.54K | 8.61% |
| Mar 2024 | 3224611 | 570.08K | 17.68% |
| Jun 2023 | -742.41K | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -960.45K | 0 | 1.15M |
| Dec 2023 | -1.46M | 0 | 2.31M |
| Mar 2024 | -937.41K | 0 | 0 |
Virios Therapeutics alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 4 |
| Apr 2024 | 4 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Virios Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 0 | 1800 |
| Aug 2023 | 40335 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PRIDGEN WILLIAM director | Common Stock | 15,335 | $1.3 | $19,997 | ||
Purchase | DUNCAN GREGORY SCOTT director, officer: CHIEF EXECUT.. | Common Stock | 25,000 | $1.25 | $31,250 | ||
Sale | WHITLEY RICHARD JAMES director | Common Stock | 1,800 | $0.26 | $466 | ||
Purchase | DUNCAN GREGORY SCOTT director, officer: CHIEF EXECUT.. | Common Stock | 7,500 | $4.52 | $33,900 | ||
Purchase | WALSH ANGELA officer: SVP OF F.. | Common Stock | 2,000 | $4.58 | $9,150 | ||
Purchase | WHITLEY RICHARD JAMES director | Common Stock | 500 | $4.53 | $2,263 | ||
Purchase | PRIDGEN WILLIAM director | Common Stock | 241 | $4.5 | $1,085 | ||
Purchase | PRIDGEN WILLIAM director | Common Stock | 13,450 | $4.38 | $58,911 | ||
Purchase | PRIDGEN WILLIAM director | Common Stock | 600 | $4.94 | $2,965 | ||
Purchase | PRIDGEN WILLIAM director | Common Stock | 2,197 | $5.46 | $12,002 |
| Quarter | Transcript |
|---|---|
| Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Greg Duncan (1965) Chairman & Chief Executive Officer | $779,320 |
| Ms. Angela Walsh (1967) Chief Financial Officer, SVice President of Fin., Corporation Sec. & Treasurer | $253,450 |
| Mr. Ralph D. Grosswald (1969) Vice President of Operations | $233,950 |
-
When is Virios Therapeutics's next earnings date?
Unfortunately, Virios Therapeutics's (VIRI) next earnings date is currently unknown.
-
Does Virios Therapeutics pay dividends?
No, Virios Therapeutics does not pay dividends.
-
How much money does Virios Therapeutics make?
Virios Therapeutics has a market capitalization of 206.50K. Virios Therapeutics made a loss 5.3M US dollars in net income (profit) last year or -$0.07 on an earnings per share basis.
-
What is Virios Therapeutics's stock symbol?
Virios Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VIRI".
-
What is Virios Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Virios Therapeutics?
Shares of Virios Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Virios Therapeutics's key executives?
Virios Therapeutics's management team includes the following people:
- Mr. Greg Duncan Chairman & Chief Executive Officer(age: 60, pay: $779,320)
- Ms. Angela Walsh Chief Financial Officer, SVice President of Fin., Corporation Sec. & Treasurer(age: 58, pay: $253,450)
- Mr. Ralph D. Grosswald Vice President of Operations(age: 56, pay: $233,950)
-
How many employees does Virios Therapeutics have?
As Jul 2024, Virios Therapeutics employs 4 workers.
-
When Virios Therapeutics went public?
Virios Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 17 Dec 2020.
-
What is Virios Therapeutics's official website?
The official website for Virios Therapeutics is virios.com.
-
Where are Virios Therapeutics's headquarters?
Virios Therapeutics is headquartered at 44 Milton Avenue, Alpharetta, GA.
-
How can i contact Virios Therapeutics?
Virios Therapeutics's mailing address is 44 Milton Avenue, Alpharetta, GA and company can be reached via phone at +86 66208655.
Virios Therapeutics company profile:
Virios Therapeutics, Inc.
virios.comNASDAQ
4
Biotechnology
Healthcare
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Alpharetta, GA 30009
CIK: 0001818844
ISIN: US92829J1043
CUSIP: 92829J104
